entertainment -WSS

entertainment

author：leisure time 2025-10-02 14:22:52 - browse：82

Eli Lilly headquarters — Kristoffer Tripplaar/AP

Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.

It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight loss drug, sold under the brand names Mounjaro and Zepbound. It was a big deal when Lilly became the first drug company ever to have a market value of $500 billion; it’s now sitting at a stunning $670 billion.

At first, the earnings report suggested the company had blasted through expectations again, announcing fourth-quarter 2023 sales of $9.35 billion, almost half a billion dollars above analysts’ expectations, and also announcing new data for Mounjaro in treating metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease previously called NASH. Initially, shares traded up 5%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Readout LOUD podcast: ALS dilemma, first MASH drug, and more

WSS

Male and female sex labels in research insufficient, scientists say

President Biden's budget: Here's what you might have missed

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Boston's new lab space is opening empty

Health tech startups drop sharply from 2021 highs

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

focus

entertainment

entertainment

How to save PrEP access — and even expand it

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

How to save PrEP access — and even expand it

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Malaria cases in Florida and Texas: Here’s what you need to know

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Tori Bowie and the unacceptable rates of Black maternal death

First U.S. drug developed to treat liver disease MASH is approved

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How the Dana

focus

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

EPA limits use of carcinogenic gas for sterilizing medical devices

Sudafed saga points to U.S. issues with evaluating older drugs

First U.S. drug developed to treat liver disease MASH is approved

Sudafed saga points to U.S. issues with evaluating older drugs

Paxlovid should be available without a positive Covid test

explore

entertainment

Wikipedia

focus